TP53 and B-cell chronic lymphocytic leukemia: The MDM2–p53 interaction therefore represents an attractive therapeutic target for CLL with functional p53, the inhibition of which would be expected to upregulate p53 levels, thereby enhancing tumor control (Figure 1) [79].